Timeline - The evolution of thalidomide and its IMiD derivatives as anticancer agents

被引：636

作者：

Bartlett, JB

Dredge, K

Dalgleish, AG

机构：

[1] Celgene Corp, Warren, NJ 07059 USA

[2] St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England

来源：

NATURE REVIEWS CANCER | 2004年 / 4卷 / 04期

关键词：

D O I：

10.1038/nrc1323

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide was originally used to treat morning sickness, but was banned in the 1960s for causing serious congenital birth defects. Remarkably, thalidomide was subsequently discovered to have anti-inflammatory and anti-angiogenic properties, and was identified as an effective treatment for multiple myeloma. A series of immunomodulatory drugs - created by chemical modification of thalidomide - have been developed to overcome the original devastating side effects. Their powerful anticancer properties mean that these drugs are now emerging from thalidomide's shadow as useful anticancer agents.

引用

收藏

页码：314 / 322

页数：10

相关论文

共 57 条

[21] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].

Hideshima, T ;

Chauhan, D ;

Shima, Y ;

Raje, N ;

Davies, FE ;

Tai, YT ;

Treon, SP ;

Lin, B ;

Schlossman, RL ;

Richardson, P ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2000, 96 (09) :2943-2950

[22] Molecular mechanisms of novel therapeutic approaches for multiple myeloma [J].

Hideshima, T ;

Anderson, KC .

NATURE REVIEWS CANCER, 2002, 2 (12) :927-937

[23]

IYER CGS, 1971, B WORLD HEALTH ORGAN, V45, P719

[24] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].

Juliusson, G ;

Celsing, F ;

Turesson, I ;

Lenhoff, S ;

Adriansson, M ;

Malm, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96

[25] Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma [J].

Kumar, S ;

Witzig, TE ;

Dispenzieri, A ;

Lacy, MQ ;

Wellik, LE ;

Fonseca, R ;

Lust, JA ;

Gertz, MA ;

Kyle, RA ;

Greipp, PR ;

Rajkumar, SV .

LEUKEMIA, 2004, 18 (03) :624-627

[26] Thalidomide as an anti-cancer agent [J].

Kumar, S ;

Witzig, TE ;

Rajkumar, SV .

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2002, 6 (02) :160-174

[27] Immunomodulatory drug costimulates T cells via the B7-CD28 pathway [J].

LeBlanc, R ;

Hideshima, T ;

Catley, LP ;

Shringarpure, R ;

Burger, R ;

Mitsiades, N ;

Mitsiades, C ;

Cheema, P ;

Chauhan, D ;

Richardson, PG ;

Anderson, KC ;

Munshi, NC .

BLOOD, 2004, 103 (05) :1787-1790

[28]

Lentzsch S, 2002, CANCER RES, V62, P2300

[29]

LENZ W, 1962, LANCET, V1, P45

[30] Effect of thalidomide on chemokine production by human microglia [J].

Lokensgard, JR ;

Hu, SX ;

van Fenema, EM ;

Sheng, WS ;

Peterson, PK .

JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (03) :983-987

← 1 2 3 4 5 6 →